Last reviewed · How we verify
Standard dose rifapentine
Standard dose rifapentine is a Small molecule drug developed by McGill University Health Centre/Research Institute of the McGill University Health Centre. It is currently in Phase 1 development. Also known as: RPT10.
At a glance
| Generic name | Standard dose rifapentine |
|---|---|
| Also known as | RPT10 |
| Sponsor | McGill University Health Centre/Research Institute of the McGill University Health Centre |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Shortened Regimen for Drug-susceptible TB in Children (PHASE3)
- Asymptomatic TB With Innovative Modified Short-course Regimens (PHASE4)
- Shorter and Safer Treatment Regimens for Latent TB (PHASE2, PHASE3)
- Pharmacokinetics of Antituberculosis Drugs in Breastfeeding Women (PHASE1)
- ThiPhiSA: New Pathways to Prevention From Community TB Screening in South Africa (NA)
- Pharmacokinetics and Safety of Double-dose Dolutegravir When Used With Rifapentine for HIV-associated Tuberculosis (PHASE2)
- Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis (PHASE3)
- Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Standard dose rifapentine CI brief — competitive landscape report
- Standard dose rifapentine updates RSS · CI watch RSS
- McGill University Health Centre/Research Institute of the McGill University Health Centre portfolio CI
Frequently asked questions about Standard dose rifapentine
What is Standard dose rifapentine?
Standard dose rifapentine is a Small molecule drug developed by McGill University Health Centre/Research Institute of the McGill University Health Centre.
Who makes Standard dose rifapentine?
Standard dose rifapentine is developed by McGill University Health Centre/Research Institute of the McGill University Health Centre (see full McGill University Health Centre/Research Institute of the McGill University Health Centre pipeline at /company/mcgill-university-health-centre-research-institute-of-the-mcgill-university-heal).
Is Standard dose rifapentine also known as anything else?
Standard dose rifapentine is also known as RPT10.
What development phase is Standard dose rifapentine in?
Standard dose rifapentine is in Phase 1.
Related
- Manufacturer: McGill University Health Centre/Research Institute of the McGill University Health Centre — full pipeline
- Also known as: RPT10
- Compare: Standard dose rifapentine vs similar drugs
- Pricing: Standard dose rifapentine cost, discount & access